Literature DB >> 6086498

Establishment and characterization of a new human hepatocellular carcinoma cell line.

L He, K J Isselbacher, J R Wands, H M Goodman, C Shih, A Quaroni.   

Abstract

A human hepatocellular carcinoma cell line (FOCUS--Friendship of China and United States) was derived from a patient with primary hepatocellular carcinoma. This cell line has been in continuous culture over an 18-mo period. The morphological and ultrastructural features of FOCUS are consistent with its neoplastic hepatocellular origin. FOCUS cells contain aspartate aminotransferase and glucose-6-phosphatase activity. In addition, alpha 1-antitrypsin, fibrinogen, alpha fetoprotein, and carcinoembryonic antigens were detectable in the cytoplasm of the cultured cells by immunochemical staining techniques. The karyotype of the FOCUS cell is human in origin and its contains human DNA sequences as detected by molecular hybridization analysis. The FOCUS cells do not show evidence of density-dependent inhibition of growth under confluent conditions. Repeated growth curves over an 18-mo period were identical, revealing a doubling time of 42 to 48 h. The malignant potential of FOCUS cells was further demonstrated by their ability to lead to gross tumor formation after subcutaneous injection into nude mice. From one of the solid tumors grown in nude mice, recultured cell lines have been established and found to have properties identical to the original FOCUS cell line. This FOCUS cell line represents an additional model for further investigation of tumor specific antigens and the relationship between hepatitis B virus (HBV) and hepatocellular carcinoma. Preliminary molecular characterization has indicated the existence of integrated HBV sequences within the FOCUS genome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086498     DOI: 10.1007/bf02619623

Source DB:  PubMed          Journal:  In Vitro        ISSN: 0073-5655


  37 in total

1.  Immune and enzyme histochemical studies of a human hepatocellular carcinoma cell line producing hepatitis B surface antigen.

Authors:  M A Gerber; E Garfinkel; S Z Hirschman; S N Thung; T Panagiotatos
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

2.  Hepatitis B surface antigen production as a growth cycle-related terminal event in PLC/PRF/5 hepatoma cells.

Authors:  J A Copeland; J Skelly; G F Mann; C R Howard; A J Zuckerman
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

3.  Prevalence of hepatitis B e antigen and its antibody as detected by radioimmunoassays.

Authors:  I K Mushahwar; L R Overby; G Frosner; F Deinhardt; C M Ling
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

4.  Electron microscopy of HBsAg from human hepatoma cell line.

Authors: 
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

5.  The influence of insulin on various enzyme activities in human and rat hepatoma cells.

Authors:  J Grimm
Journal:  Eur J Biochem       Date:  1976-04-15

6.  Establishment and some biological characteristics of human hepatoma cell lines.

Authors:  I Dor; M Namba; J Sato
Journal:  Gan       Date:  1975-08

7.  State of hepatitis B viral DNA in a human hepatoma cell line.

Authors:  P L Marion; F H Salazar; J J Alexander; W S Robinson
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

8.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Authors:  B B Knowles; C C Howe; D P Aden
Journal:  Science       Date:  1980-07-25       Impact factor: 47.728

9.  Integration pattern of hepatitis B virus DNA sequences in human hepatoma cell lines.

Authors:  E M Twist; H F Clark; D P Aden; B B Knowles; S A Plotkin
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

10.  Stages of B cell differentiation in human lymphoid tissue.

Authors:  A K Bhan; L M Nadler; P Stashenko; R T McCluskey; S F Schlossman
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  31 in total

1.  Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (I97L) in human hepatitis B virus.

Authors:  Fat-Moon Suk; Min-Hui Lin; Margaret Newman; Shann Pan; Sheng-Hsuan Chen; Jean-Dean Liu; Chiaho Shih
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  The major histocompatibility complex class I antigen-binding protein p88 is the product of the calnexin gene.

Authors:  K Galvin; S Krishna; F Ponchel; M Frohlich; D E Cummings; R Carlson; J R Wands; K J Isselbacher; S Pillai; M Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

3.  Tight clustering of human hepatitis B virus integration sites in hepatomas near a triple-stranded region.

Authors:  C Shih; K Burke; M J Chou; J B Zeldis; C S Yang; C S Lee; K J Isselbacher; J R Wands; H M Goodman
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

4.  A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype.

Authors:  S Tanaka; J R Wands
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

5.  Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma.

Authors:  Yoshito Tomimaru; Hironori Koga; Hirohisa Yano; Suzanne de la Monte; Jack R Wands; Miran Kim
Journal:  Liver Int       Date:  2013-05-08       Impact factor: 5.828

6.  Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.

Authors:  B Bressac; K M Galvin; T J Liang; K J Isselbacher; J R Wands; M Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

7.  DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression.

Authors:  Kelong Ma; Yinghua He; Hongyu Zhang; Qi Fei; Dandan Niu; Dongmei Wang; Xia Ding; Hua Xu; Xiaoping Chen; Jingde Zhu
Journal:  J Biol Chem       Date:  2011-11-23       Impact factor: 5.157

8.  Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.

Authors:  L Lavaissiere; S Jia; M Nishiyama; S de la Monte; A M Stern; J R Wands; P A Friedman
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

9.  Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma.

Authors:  Martin Golkowski; Ho-Tak Lau; Marina Chan; Heidi Kenerson; Venkata Narayana Vidadala; Anna Shoemaker; Dustin J Maly; Raymond S Yeung; Taranjit S Gujral; Shao-En Ong
Journal:  Cell Syst       Date:  2020-08-04       Impact factor: 10.304

10.  Isolation, characterization, and distribution of an unusual pancreatic human secretory protein.

Authors:  J Gross; R I Carlson; A W Brauer; M N Margolies; A L Warshaw; J R Wands
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.